Pricing & Reimbursement

Outcomes-Based Contracting Gain Steam

Amgen’s recent offer to refund to health plans the cost of its statin add-on therapy Repatha for eligible patients who take it and then suffer a heart attack or stroke highlights the extent pharmaceutical companies are willing to go to overcome insurance access barriers to expensive, groundbreaking therapies. The refund offer was announced along with […]

Paying for Performance: EFPIA’s Catch-22 for European Drug Pricing

A leaked internal paper could signal a tidal shift in European drug pricing as companies and payers continue their combined march toward value-based pricing. However, the concession by industry could come at a price to payers, namely their reliance on cost containment measures such as external reference pricing, which suggests that this roadmap is just […]